243 related articles for article (PubMed ID: 28006952)
1. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
2. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
3. IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.
Karasavvas N; Karnasuta C; Savadsuk H; Madnote S; Inthawong D; Chantakulkij S; Rittiroongrad S; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Siriyanon V; Andrews CA; Barnett SW; Tartaglia J; Sinangil F; Francis DP; Robb ML; Michael NL; Ngauy V; de Souza MS; Paris RM; Excler JL; Kim JH; O'Connell RJ;
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1178-86. PubMed ID: 26234467
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
5. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
Chung AW; Ghebremichael M; Robinson H; Brown E; Choi I; Lane S; Dugast AS; Schoen MK; Rolland M; Suscovich TJ; Mahan AE; Liao L; Streeck H; Andrews C; Rerks-Ngarm S; Nitayaphan S; de Souza MS; Kaewkungwal J; Pitisuttithum P; Francis D; Michael NL; Kim JH; Bailey-Kellogg C; Ackerman ME; Alter G
Sci Transl Med; 2014 Mar; 6(228):228ra38. PubMed ID: 24648341
[TBL] [Abstract][Full Text] [Related]
6. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
Yates NL; Liao HX; Fong Y; deCamp A; Vandergrift NA; Williams WT; Alam SM; Ferrari G; Yang ZY; Seaton KE; Berman PW; Alpert MD; Evans DT; O'Connell RJ; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Pinter A; Zolla-Pazner S; Gilbert PB; Nabel GJ; Michael NL; Kim JH; Montefiori DC; Haynes BF; Tomaras GD
Sci Transl Med; 2014 Mar; 6(228):228ra39. PubMed ID: 24648342
[TBL] [Abstract][Full Text] [Related]
8. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
9. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
Pollara J; Bonsignori M; Moody MA; Liu P; Alam SM; Hwang KK; Gurley TC; Kozink DM; Armand LC; Marshall DJ; Whitesides JF; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; O'Connell RJ; Kim JH; Michael NL; Montefiori DC; Tomaras GD; Liao HX; Haynes BF; Ferrari G
J Virol; 2014 Jul; 88(14):7715-26. PubMed ID: 24807721
[TBL] [Abstract][Full Text] [Related]
11. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
[TBL] [Abstract][Full Text] [Related]
12. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
Montefiori DC; Karnasuta C; Huang Y; Ahmed H; Gilbert P; de Souza MS; McLinden R; Tovanabutra S; Laurence-Chenine A; Sanders-Buell E; Moody MA; Bonsignori M; Ochsenbauer C; Kappes J; Tang H; Greene K; Gao H; LaBranche CC; Andrews C; Polonis VR; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Self SG; Berman PW; Francis D; Sinangil F; Lee C; Tartaglia J; Robb ML; Haynes BF; Michael NL; Kim JH
J Infect Dis; 2012 Aug; 206(3):431-41. PubMed ID: 22634875
[TBL] [Abstract][Full Text] [Related]
13. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion.
Alam SM; Liao HX; Tomaras GD; Bonsignori M; Tsao CY; Hwang KK; Chen H; Lloyd KE; Bowman C; Sutherland L; Jeffries TL; Kozink DM; Stewart S; Anasti K; Jaeger FH; Parks R; Yates NL; Overman RG; Sinangil F; Berman PW; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Karasavva N; Rerks-Ngarm S; Kim JH; Michael NL; Zolla-Pazner S; Santra S; Letvin NL; Harrison SC; Haynes BF
J Virol; 2013 Feb; 87(3):1554-68. PubMed ID: 23175357
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
Kim JH; Excler JL; Michael NL
Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
[TBL] [Abstract][Full Text] [Related]
15. Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.
Nelson CS; Pollara J; Kunz EL; Jeffries TL; Duffy R; Beck C; Stamper L; Wang M; Shen X; Pickup DJ; Staats HF; Hudgens MG; Kepler TB; Montefiori DC; Moody MA; Tomaras GD; Liao HX; Haynes BF; Ferrari G; Fouda GGA; Permar SR
J Virol; 2016 May; 90(10):4951-4965. PubMed ID: 26937027
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
[TBL] [Abstract][Full Text] [Related]
17. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.
Tay MZ; Liu P; Williams LD; McRaven MD; Sawant S; Gurley TC; Xu TT; Dennison SM; Liao HX; Chenine AL; Alam SM; Moody MA; Hope TJ; Haynes BF; Tomaras GD
PLoS Pathog; 2016 Aug; 12(8):e1005817. PubMed ID: 27579713
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
[TBL] [Abstract][Full Text] [Related]
20. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
Rolland M; Edlefsen PT; Larsen BB; Tovanabutra S; Sanders-Buell E; Hertz T; deCamp AC; Carrico C; Menis S; Magaret CA; Ahmed H; Juraska M; Chen L; Konopa P; Nariya S; Stoddard JN; Wong K; Zhao H; Deng W; Maust BS; Bose M; Howell S; Bates A; Lazzaro M; O'Sullivan A; Lei E; Bradfield A; Ibitamuno G; Assawadarachai V; O'Connell RJ; deSouza MS; Nitayaphan S; Rerks-Ngarm S; Robb ML; McLellan JS; Georgiev I; Kwong PD; Carlson JM; Michael NL; Schief WR; Gilbert PB; Mullins JI; Kim JH
Nature; 2012 Oct; 490(7420):417-20. PubMed ID: 22960785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
